+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Histone Modifications in Therapy, Vol 19. Translational Epigenetics

  • ID: 4991044
  • Book
  • August 2020
  • Region: Global
  • 424 Pages
  • Elsevier Science and Technology
1 of 3

Histone Modifications in Therapy provides an in-depth analysis of the role of histone mechanisms in major diseases and the promise of targeting histone modifications for disease prevention and treatment. Here, researchers, clinicians and students will discover a thorough, evidence-based discussion of the biology of histones, the diseases engaged by aberrant histone modifications, and pathways with therapeutic potential. Expert chapter addresses the role of histone modifications across a variety of disorders, including cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, autoimmune and inflammatory disorders, among others. In relation to these disease types, histone modifications are discussed, both as mechanisms of prevention and possible treatment.

A concluding chapter brings together future perspectives for targeting histone modifications in therapy and next steps in research.

  • Examines the use of histone modifications in disease prevention and therapy
  • Explores the role of histone modifications in cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, and inflammatory disease, among others
  • Features chapters from a broad range of international authors and disease specialists
Note: Product cover images may vary from those shown
2 of 3

1. Therapeutic perspectives for targeting histone modifications in mental retardation 2. Role of histone acetylation and methylation in depression 3. Epigenetic treatment of neurodegenerative diseases 4. Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease 5. A prospective view of targeting histone modifications for Autism Spectrum Disorder

Section II. Targeting histone modifications for cancer treatment 6.  HDAC inhibitors in cancer therapy 7. Lysine methyltransferase drug targets in cancer 8. Targeting EZH2 in cancer 9. Targeting DOT1L for mixed lineage rearranged leukemia 10. Targeting bromodomains in cancer treatment and other diseases 11. Histone demethylase inhibitors and their potential in cancer treatment 12. IDH mutations in cancer and progress toward development of targeted therapeutics

Section III. Targeting histone modifications for cardiovascular diseases and diabetes 13. Histone modification for cardiovascular prevention and therapeutics 14. Modulation of histone modification as a potential preventive and therapeutic approach for cardiovascular diseases 15. Epigenetics as an emerging approach to treat atherosclerosis 16. The potentiality of epigenetic drugs for diabetes and obesity 17. Epigenetic modifications for diabetic retinopathy 18. Targeting histone modifications in cancer immunotherapy 19. Epigenetic drug development for autoimmune and inflammatory diseases 20. Perspectives on epigenetic-based immune intervention for rheumatic diseases 21. The potential for targeted rewriting of epigenetic marks in Chronic obstructive pulmonary disease as a new therapeutic approach

Section V. Targeting histone modifications for infectious disease 22. The therapeutic potential of epigenetic manipulation during infectious diseases 23. Targeting histone deacetylases for bacterial infections 24. Targeting histone methyltransferases EZH2/1 to suppress infection by diverse viral pathogens

Note: Product cover images may vary from those shown
3 of 3


4 of 3
Castelo-Branco, Pedro
Pedro Castelo Branco completed his doctorate in molecular biology at Oxford University in 2005, followed by post-doctoral fellowships at Harvard University and the University of Toronto. Since 2014 he is a Professor in the Department of Biomedical Sciences and Medicine and head of the Epigenetics in Human Disease laboratory , at the University of the Algarve. His scientific interests include the identification of specific epigenetic signatures throughout carcinogenesis and targeted methylation/demethylation as a therapeutic approach.
Jeronimo, Carmen
Dr. Carmen Jerónimo is the Head of the Cancer Biology & Epigenetics Group at the Portuguese Oncology Institute of Porto (IPO Porto) & Invited Associate Professor at the Institute of Biomedical Sciences Abel Salazar - University of Porto. She obtained her PhD in Biomedical Sciences (2001) and Habilitation in Pathology and Molecular Genetics (2011) from the University of Porto. Her PhD project was carried out at Johns Hopkins University (JHU), Baltimore, USA. From 2002 until 2007, she was a Post-doctoral Fellow and Invited Researcher at IPO Porto and JHU (2003). Her current research characterizes the epigenome of tumor cells, through the establishment of the profile of DNA methylation, of histone modifications and alteration patterns of miRNA, of genes related to tumorigenesis and the identification of functional changes involved in the breakdown of cell epigenetic homeostasis. Dr. Jerónimo has authored or co-authored more than 160 international scientific publications, including 4 book chapters and several review articles. She has supervised 3 PhD theses and 30 Master dissertations and collaborated in a patent submission (Methods and biomarkers for detection of bladder cancer US 20130210011/ EP 2630261 A1/ WO 2012052844 A1).
Note: Product cover images may vary from those shown